Straits Times Index
3,367.90 +29.33 (+0.88%) S&P 500
5,478.54 +3.45 (+0.06%) Dow
39,105.56 -63.96 (-0.16%) Nasdaq
17,922.51 +43.21 (+0.24%) Bitcoin USD
61,855.85 -1,286.79 (-2.04%) CMC Crypto 200
1,306.67 -37.84 (-2.81%)
INDV Nov 2024 17.500 call
| Previous close | 2.1800 |
| Open | 1.5000 |
| Bid | 0.5500 |
| Ask | 1.9000 |
| Strike | 17.50 |
| Expiry date | 2024-11-15 |
| Day's range | 1.5000 - 1.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.84k |
PR NewswireIndivior Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (OPVEE 2.7mg) and IN Naloxone (4 mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression and Cardiac Arrest
Indivior PLC (LSE/Nasdaq: INDV) today announced the publication of a modeling study in Frontiers in Psychiatry that predicts OPVEE (nalmefene) nasal spray (2.7 mg nalmefene, equivalent to 3 mg of nalmefene hydrochloride) resulted in larger reductions in the incidence of simulated cardiac arrest following overdose from high doses of potent synthetic opioids, compared to a 4 mg dose of IN naloxone.
- PR Newswire
Indivior Announces Dosing of First Subject with INDV-2000 in a Phase 2 Study Assessing the Safety and Efficacy of INDV-2000 in Individuals with Opioid Use Disorder
Indivior PLC (LSE/Nasdaq: INDV) today announced the dosing of the first subject with INDV-2000 in a Phase 2 double-blind, placebo controlled, randomized, dose-ranging study to assess the safety and efficacy of INDV-2000 over 3 months in treatment-seeking individuals with Opioid Use Disorder (OUD) (NCT06384157). The purpose of this proof-of-concept study is to measure safety and efficacy and to determine the dose-response relationship for INDV-2000 in participants with moderate to severe OUD who
Simply Wall St.With 59% ownership, Indivior PLC (LON:INDV) boasts of strong institutional backing
Key Insights Institutions' substantial holdings in Indivior implies that they have significant influence over the...
